JACC. Case reports · 2025
Cardiac Amyloid, The Great Imitator.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fox Nolan R, Fox Nicholas J, Newman Emily, Osler Brian, Storozynsky Eugene
Аннотация
BACKGROUND: Although endomyocardial biopsy (EMB) is the criterion standard for diagnosis of infiltrative cardiac disease, cardiac sarcoidosis (CS) or cardiac amyloid can be diagnosed noninvasively through both clinical suspicion and advanced imaging techniques of cardiac magnetic resonance imaging (CMR) or cardiac positron emission tomography (PET).
CASE SUMMARY: A 79-year-old man with mediastinal sarcoidosis presented with new chest pain and a right bundle branch block, raising concern for CS. CMR and cardiac PET also supported the diagnosis of CS, but EMB ultimately revealed transthyretin amyloid cardiomyopathy. The patient was started on tafamidis and showed improvement at 1-year follow-up.
DISCUSSION: This case shows that cardiac amyloidosis can masquerade as CS when following conventional diagnostic pathways. Without EMB, this patient would have been treated with steroids for CS, which is not a risk-free therapy.
TAKE-HOME MESSAGE: It is possible to misdiagnose CS in the setting of amyloidosis when using advanced noninvasive imaging techniques such as CMR and cardiac PET.
CASE SUMMARY: A 79-year-old man with mediastinal sarcoidosis presented with new chest pain and a right bundle branch block, raising concern for CS. CMR and cardiac PET also supported the diagnosis of CS, but EMB ultimately revealed transthyretin amyloid cardiomyopathy. The patient was started on tafamidis and showed improvement at 1-year follow-up.
DISCUSSION: This case shows that cardiac amyloidosis can masquerade as CS when following conventional diagnostic pathways. Without EMB, this patient would have been treated with steroids for CS, which is not a risk-free therapy.
TAKE-HOME MESSAGE: It is possible to misdiagnose CS in the setting of amyloidosis when using advanced noninvasive imaging techniques such as CMR and cardiac PET.